| 朱咪咪,赵丽丽,别福鑫,吴珊珊,张 丽.信必可都保对慢性阻塞性肺疾病患者树突细胞的调节[J].,2019,19(2):308-311 |
| 信必可都保对慢性阻塞性肺疾病患者树突细胞的调节 |
| Effect of Symbicort Turbuhaler on Patients with Chronic Obstructive Pulmonary Disease of Peripheral Blood Dendritic Cells |
| 投稿时间：2018-04-12 修订日期：2018-05-04 |
| DOI：10.13241/j.cnki.pmb.2019.02.023 |
| 中文关键词: 慢性阻塞性肺疾病 树突细胞 信必可都保 流式细胞分析术 |
| 英文关键词: COPD Dendritic cells Symbicort turbuhaler Flow cytometry |
| 基金项目:黑龙江省卫生计生委科研基金项目(2016-389) |
|
| 摘要点击次数: 791 |
| 全文下载次数: 548 |
| 中文摘要: |
| 摘要 目的：探讨布地奈德/福莫特罗吸入剂(商品名：信必可都保)对于慢性阻塞性肺疾病（chronic obstructive pulmonary disease COPD）患者外周血中树突状细胞（dendritic cell DCs）亚群、肺功能以及炎症反应因子的影响。方法：选取符合入组标准的COPD急性加重期患者，共80例，随机分成2组，每组40人。对照组给予常规对症治疗，实验组在此基础上给予信必可都保吸入，观察入组对象治疗前、治疗4周后两组患者外周血树突状细胞亚群(mDCs和pDCs)的水平、C反应蛋白(C-reactive protein CRP)、白细胞计数表达水平及CAT评分、肺功能的变化。结果：用药后mDCs和pDCs占外周血的百分比及mDCs/pDCs实验组及对照组均较用药前明显降低(P>0.05)，实验组优于对照组低，但差异无明显的统计学意义(P>0.05)。用力肺活量(FVC)、FEV1 占预计值百分比(FEV1%)、FEV1/FVC、CAT评分两组均较用药前有所改善，实验组较与对照组更明显(P<0.05)。用药后C反应蛋白(CRP)、白细胞计数(WBC)较用药前有所改善，但用药后实验组与对照组相比无统计学差异(P>0.05)。结论：信必可都保可有效改善COPD患者肺功能，改善其临床症状，但对树突细胞亚群的影响不明显。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Budesonide/formott on the peripheral blood dendritic cell subgroup, lung func- tion and inflammatory factors in patients with chronic obstructive pulmonary disease. Methods: The patients with acute exacerbation of COPD were selected as the target group, 80 cases were randomly divided into 2 groups, each group was 40. The control group was treated with conventional symptomatic treatment, The experimental group was given symbicort turbuhaler inhalation on the basis of this. after 4 weeks by flow cytometry respectively four fluorescence detection of two groups of patients with peripheral blood dendritic cell subsets analysis treatment before treatment, (mDCs and pDCs), the level of C reactive protein (CRP), the expression level of white blood cell count and CAT score, pulmonary function. Results: The percentage of mDCs and pDCs in the peripheral blood and the mDCs/pDCs ex- perimental group and the control group were significantly lower than those before the medication (P>0.05), and the experimental group was lower than the control group, but there was no significant difference between the experimental group and the control group (P>0.05). The two groups of the forced vital capacity (FVC), the percentage of FEV1 (FEV1%), FEV1/FVC and CAT were all better than those be- fore the medication, and the experimental group was more obvious than the control group (P<0.05). After treatment, C reactive protein (CRP) and white blood cell count(WBC) were improved compared with those before treatment, but there was no significant difference between the experimental group and the control group after treatment (P>0.05). Conclusion: Symbicort can significantly improve lung function, reduce medical costs and improve clinical symptoms in patients with chronic obstructive pulmonary disease, but has little effect on dendritic cell subsets. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
